Teachers Retirement System of The State of Kentucky trimmed its holdings in shares of Elanco Animal Health (NYSE:ELAN) by 18.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 751,544 shares of the company’s stock after selling 166,855 shares during the period. Teachers Retirement System of The State of Kentucky owned approximately 0.19% of Elanco Animal Health worth $16,121,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of ELAN. Janus Henderson Group PLC boosted its holdings in shares of Elanco Animal Health by 209.7% during the 1st quarter. Janus Henderson Group PLC now owns 30,788,858 shares of the company’s stock worth $689,364,000 after buying an additional 20,846,120 shares in the last quarter. Aristotle Capital Management LLC bought a new position in shares of Elanco Animal Health during the 1st quarter worth approximately $243,886,000. UBS Group AG boosted its holdings in shares of Elanco Animal Health by 1,746.9% during the 2nd quarter. UBS Group AG now owns 11,046,430 shares of the company’s stock worth $236,946,000 after buying an additional 10,448,327 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Elanco Animal Health by 12.5% in the 1st quarter. Primecap Management Co. CA now owns 34,435,759 shares of the company’s stock worth $771,017,000 after purchasing an additional 3,837,394 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Elanco Animal Health by 24.3% in the 1st quarter. State Street Corp now owns 12,639,827 shares of the company’s stock worth $283,006,000 after purchasing an additional 2,472,266 shares in the last quarter. Hedge funds and other institutional investors own 98.22% of the company’s stock.
ELAN has been the topic of a number of recent research reports. Credit Suisse Group initiated coverage on Elanco Animal Health in a report on Wednesday, August 12th. They issued a “neutral” rating and a $27.00 target price on the stock. Argus increased their target price on Elanco Animal Health from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Morgan Stanley upgraded Elanco Animal Health from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $24.00 to $31.00 in a report on Thursday, August 20th. They noted that the move was a valuation call. Bank of America increased their target price on Elanco Animal Health from $26.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Finally, Cleveland Research cut Elanco Animal Health from a “neutral” rating to an “underperform” rating and set a $19.00 price objective on the stock. in a research note on Monday, July 27th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $26.83.
Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Thursday, July 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.07. Elanco Animal Health had a positive return on equity of 4.68% and a negative net margin of 3.63%. The firm had revenue of $586.30 million during the quarter, compared to analyst estimates of $555.84 million. On average, analysts forecast that Elanco Animal Health will post 0.59 EPS for the current fiscal year.
In other news, insider Todd S. Young acquired 7,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average price of $23.91 per share, with a total value of $167,370.00. Following the acquisition, the insider now owns 41,513 shares in the company, valued at approximately $992,575.83. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Art A. Garcia acquired 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average cost of $24.76 per share, with a total value of $49,520.00. Following the acquisition, the director now owns 9,055 shares in the company, valued at approximately $224,201.80. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 38,580 shares of company stock valued at $1,021,586. Insiders own 0.12% of the company’s stock.
Elanco Animal Health Company Profile
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Further Reading: Quiet Period
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.